drugset

drugset / Trial / NCT02993055

A Study to Assess Ulimorelin in Healthy Subjects

NCT02993055 ↗

Phase 1 Completed 39 enrolled Lyric Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

A Phase I dose escalation study involving healthy subjects.

Timeline

Start: 2015-01
Primary completion: 2015-11
Completion: 2015-11

Publications

James J, Mair S, Doll W, Sandefer E, Wurtman D, Maurer A, Deane AM, Harris MS. The effects of ulimorelin, a ghrelin agonist, on liquid gastric emptying and colonic transit in humans. Neurogastroenterol Motil. 2020 Mar;32(3):e13784. doi: 10.1111/nmo.13784. Epub 2020 Feb 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ulimorelin	Small molecule	80 ug/kg	—
Subject	Ulimorelin	Small molecule	600 ug/kg	—
Subject	Ulimorelin	Small molecule	1200 ug/kg	—

Indications

No indication recorded.